文献速递神经肿瘤

曲美替尼治疗进展性儿童低级别胶质瘤

Trametinib for progressive pediatric low-grade gliomas.
PubMed 文献 · J Neurooncol · 2018-08-10

本文回顾性描述6例散发性毛细胞型星形细胞瘤患儿,在常规治疗进展后接受MEK抑制剂曲美替尼治疗。中位治疗时间11个月,观察到2例部分缓解和3例轻微缓解,最常见毒性为皮疹和胃肠道症状。作者认为曲美替尼似乎是难治性儿童低级别胶质瘤的合适选择,值得进一步研究。

要点

  • 6例进展性儿童毛细胞型星形细胞瘤接受曲美替尼治疗,中位治疗11个月。
  • 最佳疗效为2例部分缓解和3例轻微缓解,1例疾病进展停药。
  • 最常见毒性为轻度至中度严重皮疹和胃肠道症状,2例因皮肤毒性减量。

核心结论

  • 曲美替尼似乎是难治性儿童低级别胶质瘤的合适选择,值得在疾病进展时进一步研究。

研究设计与样本

  • 回顾性图表综述,描述6例散发性毛细胞型星形细胞瘤患儿在常规治疗进展后接受曲美替尼治疗。

主要发现

  • 诊断时中位年龄2.3岁(范围11个月至8.5岁)。
  • 5例检出KIAA1549-BRAF融合,1例检出FGFR1/NF1/PTPN11热点突变。
  • 所有患者既往接受至少1线化疗(范围1-4线),中位治疗时间11个月(范围4-20个月)。
  • 最佳疗效为2例部分缓解和3例轻微缓解,其中3例仍在治疗中;1例疾病进展者停药。
  • 最常见毒性为轻度至中度严重皮疹和胃肠道症状,2例因皮肤毒性减量;生活质量极好,就医次数减少,生活接近正常。

临床怎么用

  • 作者认为曲美替尼似乎是难治性儿童低级别胶质瘤的合适选择,值得在疾病进展时进一步研究。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pediatric pilocytic astrocytomas (PAs) are low grade gliomas and the most common brain tumors in children. They often represent a therapeutic challenge when incompletely resected as they can recur and progress despite the use of several lines of chemotherapeutic agents or even radiation therapy. Genetic alterations leading to activation of the mitogen-activated-protein-kinase pathway are a hallmark of this disease and offer an interesting therapeutic alternative through the use of targeted inhibitors. METHODS: Here, we describe six children with sporadic PA who were treated with trametinib, a MEK inhibitor, following progression under conventional therapies. Retrospective chart review was performed. RESULTS: The median age at diagnosis was 2.3 years (y) old [range 11 months (m)-8.5 y old]. KIAA1549-BRAF fusion was identified in five cases, and hotspot FGFR1/NF1/PTPN11 mutations in one. All patients received at least one previous line of chemotherapy (range 1-4). The median time on treatment was 11 m (range 4-20). Overall, we observed two partial responses and three minor responses as best response; three of these patients are still on therapy. Treatment was discontinued in the patient with progressive disease. The most frequent toxicities were minor to moderately severe skin rash and gastro-intestinal symptoms. Two patients had dose reduction due to skin toxicity. Quality of life was excellent with decreased hospital visits and a close to normal life. CONCLUSION: Trametinib appears to be a suitable option for refractory pediatric low-grade glioma and warrants further investigations in case of progression.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Kondyli M, Larouche V, Saint-Martin C, et al. Trametinib for progressive pediatric low-grade gliomas. J Neurooncol. 2018. PMID: 30097824. doi:10.1007/s11060-018-2971-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。